Sanhuang Jingshiming Pills for wet age-related macular degeneration
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a traditional Chinese medicine pill, Sanhuang Jingshiming, for people with a specific type of wet age-related macular degeneration (nAMD) that is active. It aims to see if the pill can help improve vision and is safe compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 50 and 85 years old.
- Have a diagnosis of wet age-related macular degeneration (nAMD) that is currently active in the study eye.
- Meet a specific traditional Chinese medicine pattern involving Qi-Yin deficiency and Phlegm-Blood Stasis.
- Have a certain level of vision loss in the study eye (able to read 25 to 78 letters on an eye chart).
- Not have other eye diseases like glaucoma, diabetic eye disease, or severe scar tissue in the center of the vision.
- Not have had certain treatments for nAMD, such as anti-VEGF injections, within the past few months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral tablet for people with wet age-related macular degeneration. It may offer a new way to treat the condition without frequent eye injections.
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This study tests a new medicine called SKG0106, given as an injection into the eye, for people with wet age-related macular degeneration (AMD). It aims to see if it is safe and effective in treating the leaky blood vessels that cause vision loss.
This trial tests an investigational eye injection called AL-001 for people with wet age-related macular degeneration (AMD) that has responded to previous anti-VEGF treatment. The goal is to see if it improves vision and is safe.
Hear when a new AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.